Year: 2004 Source: American Journal of Psychiatry, v.161, no.9, (September 2004), p.1558-1563 SIEC No: 20060149

The U.S. Food & Drug AdministrationÕs 1998 Belmont Report outlines 3 domains of ethical conduct, which have posed dilemmas, on the protection of human research subjects. These issues include questions about suicidal patientsÕ capacity to provide informed consent, the risk of some lethal outcomes, the possibility of suicide risk associated with patientsÕ right to discontinue the study treatment, & the need for a high level of monitoring of suicidal patients. The authors describe the design of a randomized, controlled trial of pharmacotherapy for suicidal behaviour in bipolar disorder. (27 refs)